Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
1.
Microbiol Spectr ; 12(4): e0337223, 2024 Apr 02.
Article in English | MEDLINE | ID: mdl-38466127

ABSTRACT

Foot-and-mouth disease (FMD) is one of the most devastating diseases of livestock which can cause significant economic losses, especially when introduced to FMD-free countries. FMD virus (FMDV) belongs to the family Picornaviridae and is antigenically heterogeneous with seven established serotypes. The prevailing preventive and control strategies are limited to restriction of animal movement and elimination of infected or exposed animals, which can be potentially combined with vaccination. However, FMD vaccination has limitations including delayed protection and lack of cross-protection against different serotypes. Recently, antiviral drug use for FMD outbreaks has increasingly been recognized as a potential tool to augment the existing early response strategies, but limited research has been reported on potential antiviral compounds for FMDV. FMDV 3C protease (3Cpro) cleaves the viral-encoded polyprotein into mature and functional proteins during viral replication. The essential role of viral 3Cpro in viral replication and the high conservation of 3Cpro among different FMDV serotypes make it an excellent target for antiviral drug development. We have previously reported multiple series of inhibitors against picornavirus 3Cpro or 3C-like proteases (3CLpros) encoded by coronaviruses or caliciviruses. In this study, we conducted structure-activity relationship studies for our in-house focused compound library containing 3Cpro or 3CLpro inhibitors against FMDV 3Cpro using enzyme and cell-based assays. Herein, we report the discovery of aldehyde and α-ketoamide inhibitors of FMDV 3Cpro with high potency. These data inform future preclinical studies that are related to the advancement of these compounds further along the drug development pathway.IMPORTANCEFood-and-mouth disease (FMD) virus (FMDV) causes devastating disease in cloven-hoofed animals with a significant economic impact. Emergency response to FMD outbreaks to limit FMD spread is critical, and the use of antivirals may overcome the limitations of existing control measures by providing immediate protection for susceptible animals. FMDV encodes 3C protease (3Cpro), which is essential for virus replication and an attractive target for antiviral drug discovery. Here, we report a structure-activity relationship study on multiple series of protease inhibitors and identified potent inhibitors of FMDV 3Cpro. Our results suggest that these compounds have the potential for further development as FMD antivirals.


Subject(s)
Foot-and-Mouth Disease Virus , Foot-and-Mouth Disease , Animals , Foot-and-Mouth Disease Virus/metabolism , Peptide Hydrolases/metabolism , Serogroup , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease/prevention & control , Endopeptidases/metabolism , 3C Viral Proteases , Antiviral Agents/pharmacology
2.
Viruses ; 15(2)2023 01 30.
Article in English | MEDLINE | ID: mdl-36851604

ABSTRACT

Foot-and-mouth disease (FMD) is an acute contagious disease of cloven-hoofed animals such as cattle, pigs, and sheep. Current emergency FMD vaccines are of limited use for early protection because their protective effect starts 7 days after vaccination. Therefore, antiviral drugs or additives are used to rapidly stop the spread of the virus during FMD outbreaks. Manganese (Mn2+) was recently found to be an important substance necessary for the host to protect against DNA viruses. However, its antiviral effect against RNA viruses remains unknown. In this study, we found that Mn2+ has antiviral effects on the FMD virus (FMDV) both in PK15 cells and mice. The inhibitory effect of Mn2+ on FMDV involves NF-κB activation and up-regulation of interferon-stimulated genes. Animal experiments showed that Mn2+ can be highly effective in protecting C57BL/6N mice from being infected with FMDV. Overall, we suggest Mn2+ as an effective antiviral additive for controlling FMDV infection.


Subject(s)
Antiviral Agents , Foot-and-Mouth Disease Virus , Foot-and-Mouth Disease , Manganese , Animals , Cattle , Mice , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Interferons , Manganese/pharmacology , Manganese/therapeutic use , Mice, Inbred C57BL , Sheep , Swine , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease/virology , Cell Line
3.
Antiviral Res ; 208: 105425, 2022 12.
Article in English | MEDLINE | ID: mdl-36181971

ABSTRACT

Foot-and-mouth disease (FMD) is a contagious disease affecting cloven-hoofed animals. Its transmissibility and antigenic variety make this disease difficult to control. Antiviral agents are expected to have an immediate effect that is independent of viral antigenicity; thus, they can serve as effective tools for inhibiting the spread of the causative agent, the FMD virus (FMDV), from infected animals. In this study, we investigated the antiviral activity of a pyrazinecarboxamide derivative, T-1105, against FMDV. Cytopathic effect inhibition assays revealed that T-1105 strongly inhibited the replication of 28 reference strains of all seven FMDV serotypes at non-cytotoxic concentrations. The antiviral effect of T-1105 against FMDV was also evaluated by experimental infection of domestic pigs. T-1105 was administered orally to pigs starting 1 h before or 6 h after the inoculation of a porcinophilic FMDV serotype O, topotype CATHAY. None of the pigs administered with T-1105 showed clinical signs of FMD. Moreover, no infectious FMDVs or FMDV-specific genes were detected in their sera, oral and nasal discharges, or tissues collected 48 h after virus inoculation. These findings strongly suggest that administration of T-1105 is effective in controlling the spread of FMDV in pigs.


Subject(s)
Foot-and-Mouth Disease Virus , Foot-and-Mouth Disease , Swine , Animals , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease/prevention & control , Antiviral Agents/therapeutic use , Pyrazines/pharmacology
4.
Antiviral Res ; 205: 105384, 2022 09.
Article in English | MEDLINE | ID: mdl-35863499

ABSTRACT

Foot-and-mouth disease (FMD) is an acute contagious disease of cloven-hoofed animals such as cows, pigs, sheep, and deer. The current emergency FMD vaccines, to induce early protection, have limited use, as their protective effect in pigs does not begin until 7 days after vaccination. Therefore, the use of antiviral agents would be required for reducing the spread of foot-and-mouth disease virus (FMDV) during outbreaks. Vesatolimod (GS-9620), a toll-like receptor 7 agonist, is an antiviral agent against various human disease-causing viruses. However, its antiviral effect against FMDV has not been reported yet. The aim of this study was to investigate the antiviral effects of GS-9620 against FMDV both in vitro and in vivo. The inhibitory effect of GS-9620 on FMDV in swine cells involved the induction of porcine interferon (IFN)-α and upregulation of interferon-simulated genes. Protective effect in mice injected with GS-9620 against FMDV was maintained for 5 days after injection, and cytokines such as IFN-γ, interleukin (IL)-12, IL-6, and IFN-γ inducible protein-10 could be detected following the treatment with GS-9620. Furthermore, the combination of GS-9620 with an FMD-inactivated vaccine was found to be highly effective for early protection in mice. Overall, we suggest GS-9620 as a novel and effective antiviral agent for controlling FMDV infection.


Subject(s)
Deer , Foot-and-Mouth Disease Virus , Foot-and-Mouth Disease , Viral Vaccines , Animals , Antiviral Agents/therapeutic use , Cattle , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease/prevention & control , Humans , Interferon-alpha/pharmacology , Mice , Pteridines , Sheep , Swine
5.
J Ethnopharmacol ; 292: 115076, 2022 Jun 28.
Article in English | MEDLINE | ID: mdl-35227782

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: In China, Xiyanping (XYP) has been widely used in combination with Ribavirin (RB) for the treatment of infectious diseases. It has been found that this combination may change the severity of XYP-associated adverse events (AEs). AIM: To provide a comprehensive review about the clinal features of AEs of XYP-RB combination from randomized controlled trials, cohort studies, case-control studies, case reports, case series, and data from the National Adverse Drug Reaction Monitoring Information System (NADRMIS). MATERIALS AND METHODS: Seven electronic databases were searched in March 2021. Articles on AEs associated with XYP published from January 2004 to December 2020 in the NADRMIS were included. Data on the incidence of AEs, distribution of AEs, occurrence time of AEs, type and possible signal of AEs, primary diseases, allergic history, family history of allergies, dosage, and combination interval were extracted. RESULTS: We included 228 cases of AEs with XYP-RB combination (63 cases from randomized controlled trials, 1 from a cohort study, and 164 from the NADRMIS). The most common primary disease was hand-foot-and-mouth disease. The main age distribution was 0-6 years (118 cases, 72%) and 8 cases (6.8%) experienced serious AEs. The combination group showed a significant reduction than the RB group in the incidence of AEs in those with hand-foot-and-mouth disease (risk ratio = 0.54, 95% confidence interval = 0.38-0.78, P = 0.0008) and children with viral pneumonia (risk ratio = 0.36, 95% confidence interval = 0.14-0.95, P = 0.04). Allergic history and infusion interval were not described in the randomized controlled trials. AEs were reported in 57.9% of cases in the first combination (XYP-RB were combined for the first time) (NADRMIS), 56.4% of which were skin and appendage reactions, and the risk signal of skin and appendage reactions was a maximum (Information Component = 6.21). CONCLUSION: The major AE associated with XYP-RB combination was skin and appendage reactions. Most of the combination AEs were pseudo-allergic reactions. These findings suggest that we should increase awareness about the safety of XYP-RB combination treatment and standardize medication protocol, especially for children. Unless absolutely necessary, children should avoid combination therapy. More rigorous high-quality studies are needed to obtain more evidence.


Subject(s)
Drug-Related Side Effects and Adverse Reactions , Drugs, Chinese Herbal , Foot-and-Mouth Disease , Pneumonia, Viral , Animals , Child , Child, Preschool , Cohort Studies , Drug-Related Side Effects and Adverse Reactions/drug therapy , Drugs, Chinese Herbal/therapeutic use , Foot-and-Mouth Disease/drug therapy , Humans , Infant , Infant, Newborn , Pneumonia, Viral/drug therapy , Randomized Controlled Trials as Topic , Ribavirin/adverse effects
6.
Viruses ; 13(6)2021 06 01.
Article in English | MEDLINE | ID: mdl-34205958

ABSTRACT

Picornaviruses are non-enveloped, single-stranded RNA viruses that cause highly contagious diseases, such as polio and hand, foot-and-mouth disease (HFMD) in human, and foot-and-mouth disease (FMD) in animals. Reverse genetics and minigenome of picornaviruses mainly depend on in vitro transcription and RNA transfection; however, this approach is inefficient due to the rapid degradation of RNA template. Although DNA-based reverse genetics systems driven by mammalian RNA polymerase I and/or II promoters display the advantage of rescuing the engineered FMDV, the enzymatic functions are restricted in the nuclear compartment. To overcome these limitations, we successfully established a novel DNA-based vector, namely pKLS3, an FMDV minigenome containing the minimum cis-acting elements of FMDV essential for intracytoplasmic transcription and translation of a foreign gene. A combination of pKLS3 minigenome and the helper plasmids yielded the efficient production of uncapped-green florescent protein (GFP) mRNA visualized in the transfected cells. We have demonstrated the application of the pKLS3 for cell-based antiviral drug screening. Not only is the DNA-based FMDV minigenome system useful for the FMDV research and development but it could be implemented for generating other picornavirus minigenomes. Additionally, the prospective applications of this viral minigenome system as a vector for DNA and mRNA vaccines are also discussed.


Subject(s)
Foot-and-Mouth Disease Virus/genetics , Foot-and-Mouth Disease/virology , Gene Expression Regulation, Viral , Genome, Viral , Plasmids/genetics , RNA, Messenger/genetics , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Cell Line , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease Virus/drug effects , Gene Order , Humans , Models, Molecular , Molecular Structure , RNA, Messenger/chemistry , Structure-Activity Relationship , Transfection , Virus Replication/drug effects
7.
Microb Pathog ; 155: 104914, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33915205

ABSTRACT

Each year, foot-and-mouth disease leads to enormous economic losses to the livestock industry. Currently, the killed whole virus is widely using to control FMD. However, vaccination is constrained by lack of or incomplete protection. Therefore, along with vaccination, we need to find the antivirals against FMD. This study was conducted to investigate the antiviral potential of ivermectin against multiple serotypes of FMDV. Initially, an MTT assay was performed on the BHK-21 cell line to determine assay ivermectin cytotoxicity. Viral inhibition assays using the non-cytotoxic concentration of ivermectin were performed to check the antiviral potential of ivermectin on different stages of virus replication. At 2.5 µM and 5 µM concentrations of ivermectin, the virus titer was reduced significantly (p < 0.001) by two to three log in all three strains of viruses at both non-toxic concentrations (2.5 and 5 µM). The virus titer in strain O control was 106.0 TCID50/0.1 mL and was reduced to 104.1 TCID50/0.1 mL at a concentration of 2.5 µM and 103.10 TCID50/0.1 mL at 5 µM concentration. In the case of strain Asia-1, the virus titer was reduced to 103.8 TCID50/0.1 mL at 2.5 µM and 103.01TCID50/0.1 mL at 5 µM concentration. The titer of strain A was reduced from 105.8 TCID50/0.1 mL to 103.9 TCID50/0.1 mL at 2.5 µM concentration and 103.1 TCID50/0.1 mL at 5 µM concentration. Moreover, the virus titer was reduced more at the replication stage as compared to attachment and entry stages. This study showed the in vitro anti-FMDV potential of ivermectin for the first time and predicted its potential use against FMDV infections.


Subject(s)
Foot-and-Mouth Disease Virus , Foot-and-Mouth Disease , Animals , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Foot-and-Mouth Disease/drug therapy , Ivermectin/pharmacology , Ivermectin/therapeutic use , Serogroup
8.
Transbound Emerg Dis ; 68(4): 2531-2542, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33188655

ABSTRACT

Recently, a wound dressing formulation, (Tri-Solfen®, Medical Ethics Pty Ltd, Australia; TS) registered for use in ruminant husbandry in Australia, was registered for Foot-and-Mouth Disease (FMD) therapy in large ruminants in Laos, following clinical observations of improved welfare and healing following treatment of FMD lesions. In November 2019, an FMD outbreak in Cameroon provided an opportunity for a field trial, comparing clinical responses and recoveries to treatments on a sample of cattle (n = 36) comprising three equal groups of animals (n = 12), comparing responses to three treatments: (i) the application to lesions of TS, (ii) the administration of parenteral oxytetraycline commonly used for FMD in Cameroon; and (iii) an untreated control group (C). Appetite scores, lesion healing scores, and changes in dimensions of lesions, were recorded over a 15-day study period. Cattle treated with TS achieved both superior appetite and lesion healing scores with more rapid reduction in dimensions of lesions than other groups. Farmer observations indicated the TS treatment group had a more rapid return to eating with cessation of excessive salivation, and more rapid return of mobility (walking) with absence of overt lameness. The findings indicate that although mortality is usually low in FMD outbreaks, the disease is a debilitating and painful disorder with negative animal welfare impacts that should be addressed. All farmers expressed their desire that the product be made available for use in their region and modelling indicates that TS therapy imposes no additional financial burden on farmers, with the treatment likely to be provided at a similar or reduced cost to current treatment choices. As use of antibiotics for treatment of a viral disease potentially increases pressures for development of antimicrobial resistance and residues in the food chain, TS as an alternative non-antimicrobial therapy should be promoted for wider use in FMD outbreaks.


Subject(s)
Cattle Diseases , Foot-and-Mouth Disease Virus , Foot-and-Mouth Disease , Anesthetics, Local , Animals , Cameroon/epidemiology , Cattle , Cattle Diseases/drug therapy , Cattle Diseases/epidemiology , Disease Outbreaks/veterinary , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease/epidemiology , Foot-and-Mouth Disease/prevention & control , Ruminants
9.
Biomed Pharmacother ; 118: 109305, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31545264

ABSTRACT

Foot-and-mouth disease virus (FMDV) is an important pathogen that affects livestock breeding and causes huge economic losses worldwide. Currently, the development of antiviral agents to combat FMDV infection at the early stages is being explored. As viral replication critically depends on the host for nucleoside supply, host enzymes involved in nucleotides biosynthesis may represent potential targets for the development of antiviral agents. In the present study, the effects of IMP dehydrogenase (AVN-944 and mycophenolate mofetil) and dihydroorotate dehydrogenase (teriflunomide) inhibitors were evaluated both in vitro and in vivo. The results revealed that these compounds were effective in suppressing FMDV (O/MY98/BY/2010 and A/GD/MM/2013) infection. With regard to the antiviral mechanism, time-of-addition experiments revealed that these compounds were effective when added at the early stages of viral lifecycle (0-8 h post infection). However, exogenous guanosine/uridine eliminated the antiviral activity of these compounds. Importantly, treatment AVN-944 and teriflunomide significantly improved the survival of mice that were subcutaneously treated with FMDV. Together, the results of the present study indicate the broad-spectrum activities of anti-FMDV agents targeting IMP dehydrogenase or dihydroorotate dehydrogenase, which could be useful in developing strategies to prevent FMD.


Subject(s)
Antiviral Agents/pharmacology , Enzyme Inhibitors/pharmacology , Foot-and-Mouth Disease Virus/physiology , IMP Dehydrogenase/antagonists & inhibitors , Oxidoreductases Acting on CH-CH Group Donors/antagonists & inhibitors , Animals , Antiviral Agents/chemistry , Antiviral Agents/therapeutic use , Cell Death , Cell Line , Dihydroorotate Dehydrogenase , Enzyme Inhibitors/chemistry , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease/virology , Foot-and-Mouth Disease Virus/drug effects , Guanosine/pharmacology , IMP Dehydrogenase/metabolism , Mice, Inbred BALB C , Myocardium/pathology , Oxidoreductases Acting on CH-CH Group Donors/metabolism , Uridine/pharmacology
10.
Mol Immunol ; 114: 226-232, 2019 10.
Article in English | MEDLINE | ID: mdl-31386979

ABSTRACT

Foot and mouth disease virus (FMDV), a member of family Picornaviridae, belongs to the genus Aphthovirus, which causes foot and mouth disease (FMD), a highly transmissible disease that affects cloven-hoof animals. In spite of the fact that efficient vaccines are available, effective antiviral molecules for FMD are needed to reduce viral infection during early stages of infection. In this study, merimepodib was found to efficiently inhibit FMDV replication in a dose-dependent manner. The 50% inhibitory concentration (IC50) of merimepodib antiviral activity against two distinct FMDV strains (O/MYA98/BY/2010 and A/GD/MM/CHA/2013) was estimated to be 7.859 and 2.876 µM, respectively, while the 50% cytotoxic concentration (CC50) of merimepodib was found to be 47.74 µM. Furthermore, treatment with 30 µg merimepodib efficiently prolonged the survival time of suckling mice infected with FMDV. Taken together, these results suggested that merimepodib has the potential to be a novel antiviral agent against FMDV.


Subject(s)
Antiviral Agents/pharmacology , Carbamates/pharmacology , Foot-and-Mouth Disease Virus/drug effects , Foot-and-Mouth Disease/drug therapy , Phenylurea Compounds/pharmacology , Animals , Cell Line , Mice , Swine , Viral Vaccines/pharmacology , Virus Replication/drug effects
11.
Trop Anim Health Prod ; 51(8): 2379-2386, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31177472

ABSTRACT

The effect of multinutrient antioxidant treatment on sheep naturally infected with FMD virus was investigated in terms of general health conditions, serum proteins profile, and antioxidant/oxidant parameters. Twenty diseased sheep were divided into 4 equal groups (n = 5) and underwent certain therapeutic protocols for 8 weeks as follows: GI, infected not treated group; GII, infected and treated with the ideal and usual line of treatment against FMD virus infection; GIII, infected animals supplemented orally zinc methionine at a dose of 5 g/head/day and vitamin E with selenium-enriched yeast at the same dose level; GIV, infected animals received both the ideal treatment and antioxidants. The animals under experiment were clinically evaluated. Blood samples were obtained for the comet assay and biochemical examination at zero time and at the 8th week after treatment. Results revealed that DNA damage reduced in both GIII and GIV groups which received antioxidants. In the GI group, the activity of SOD and GPx and the level of total antioxidant capacity (TAC) markedly decreased. However, in both GIII and GIV groups treated with multinutrient antioxidants, GPx and TAC values significantly increased after treatment in comparison with the values of the same groups before treatment. After treatment with multinutrient antioxidants, α1-, ß-, and γ-globulins levels markedly increased in GII and GIII groups while α2-globulin level decreased. The improvement in healing of clinical signs and general health conditions was clear in the GIV group. Finally, FMD infection in sheep was found to be associated with oxidative stress. The use of antioxidants as therapeutic approaches recovers and improves general health conditions and performance of affected animals.


Subject(s)
Antioxidants/therapeutic use , Foot-and-Mouth Disease/drug therapy , Oxidative Stress/drug effects , Sheep Diseases/drug therapy , Animals , Antioxidants/metabolism , Antioxidants/pharmacology , Blood Proteins/metabolism , Methionine/analogs & derivatives , Methionine/therapeutic use , Organometallic Compounds/therapeutic use , Selenium/therapeutic use , Sheep , Vitamin E/therapeutic use
12.
Molecules ; 24(9)2019 May 03.
Article in English | MEDLINE | ID: mdl-31058822

ABSTRACT

Foot-and-mouth disease (FMD) is a highly contagious viral disease of cloven-hoofed animals, which has significant economic consequences in affected countries. As the currently available vaccines against FMD provide no protection until 4-7 days post-vaccination, the only alternative method to control the spread of FMD virus (FMDV) during outbreaks is the application of antiviral agents. Hence, it is important to identify effective antiviral agents against FMDV infection. In this study, we found that mizoribine has potent antiviral activity against FMDV replication in IBRS-2 cells. A time-of-drug-addition assay demonstrated that mizoribine functions at the early stage of replication. Moreover, mizoribine also showed antiviral effect on FMDV in vivo. In summary, these results revealed that mizoribine could be a potential antiviral drug against FMDV.


Subject(s)
Antiviral Agents/administration & dosage , Foot-and-Mouth Disease Virus/physiology , Foot-and-Mouth Disease/drug therapy , Ribonucleosides/administration & dosage , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Cell Line , Disease Outbreaks , Foot-and-Mouth Disease/epidemiology , Foot-and-Mouth Disease/virology , Foot-and-Mouth Disease Virus/drug effects , Gene Expression Regulation, Viral/drug effects , Mice , Ribonucleosides/chemistry , Ribonucleosides/pharmacology , Swine , Viral Proteins/metabolism , Virus Replication/drug effects
13.
Biomed Pharmacother ; 116: 108982, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31146110

ABSTRACT

Foot-and-mouth disease (FMD) is one of the most highly contagious animal disease that affects cloven-hoofed animals. However, the FMD vaccine does not provide effective protection until adaptive immune protection elicited by the vaccination occurs. Therefore, an alternative application of antiviral agents for inhibition of the FMD virus (FMDV) is needed. Here, we demonstrated that brequinar could exhibit antiviral activity in swine kidney cells (IBRS-2 cells) infected with two different FMDV serotypes. Subsequently, in vivo activity of brequinar was confirmed in a mouse model of infection. Specifically, brequinar at a concentration of 50 µg, provided 25% protection for 5 days following FMDV challenge. These results suggested that brequinar could be used as effective antiviral agent against FMD.


Subject(s)
Antiviral Agents/therapeutic use , Biphenyl Compounds/therapeutic use , Foot-and-Mouth Disease Virus/physiology , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease/virology , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Biphenyl Compounds/chemistry , Biphenyl Compounds/pharmacology , Cell Death/drug effects , Cell Line , Foot-and-Mouth Disease Virus/drug effects , Myocardium/pathology , Swine , Uridine/pharmacology
14.
Crit Rev Biotechnol ; 39(3): 306-320, 2019 May.
Article in English | MEDLINE | ID: mdl-30654663

ABSTRACT

Foot and mouth disease (FMD) is a highly contagious disease of cloven-hoofed animals, which causes severe economic losses in the livestock industry. Currently available vaccines are based on inactivated FMD virus (FMDV). Although inactivated virus vaccines have proved to be effective in FMD control, they have a number of disadvantages, including the need for high bio-containment production facilities and the lack of induction of immunological memory. Novel FMD vaccines based on the use of recombinant empty capsids have shown promising results. These recombinant empty capsids are attractive candidates because they avoid the use of virus in the production facilities but conserve its complete repertoire of conformational epitopes. However, many of these recombinant empty capsids require time-consuming procedures that are difficult to scale up. Achieving production of a novel and efficient FMD vaccine requires not only immunogenic antigens, but also industrially relevant processes. This review intends to summarize and compare the different strategies already published for the production of FMDV recombinant empty capsids, focusing on large-scale production.


Subject(s)
Capsid Proteins/genetics , Foot-and-Mouth Disease/drug therapy , Recombinant Proteins/genetics , Vaccines/genetics , Animals , Capsid/chemistry , Capsid/immunology , Capsid Proteins/immunology , Capsid Proteins/therapeutic use , Foot-and-Mouth Disease/immunology , Foot-and-Mouth Disease/virology , Foot-and-Mouth Disease Virus/drug effects , Foot-and-Mouth Disease Virus/immunology , Foot-and-Mouth Disease Virus/pathogenicity , Humans , Recombinant Proteins/immunology , Recombinant Proteins/therapeutic use , Vaccines/therapeutic use , Vaccines, Inactivated/genetics , Vaccines, Inactivated/immunology
15.
J Vet Sci ; 19(6): 788-797, 2018 Nov 30.
Article in English | MEDLINE | ID: mdl-30304889

ABSTRACT

In many countries, vaccines are used for the prevention of foot-and-mouth disease (FMD). However, because there is no protection against FMD immediately after vaccination, research and development on antiviral agents is being conducted to induce protection until immunological competence is produced. This study tested whether well-known chemicals used as RNA virus treatment agents had inhibitory effects on FMD viruses (FMDVs) and demonstrated that ribavirin showed antiviral effects against FMDV in vitro/in vivo. In addition, it was observed that combining the administration of the antiviral agents orally and complementary therapy with vaccines synergistically enhanced antiviral activity and preserved the survival rate and body weight in the experimental animals. Antiviral agents mixed with an adjuvant were inoculated intramuscularly along with the vaccines, thereby inhibiting virus replication after injection and verifying that it was possible to induce early protection against viral infection prior to immunity being achieved through the vaccine. Finally, pigs treated with antiviral agents and vaccines showed no clinical signs and had low virus excretion. Based on these results, it is expected that this combined approach could be a therapeutic and preventive treatment for early protection against FMD.


Subject(s)
Antiviral Agents/therapeutic use , Foot-and-Mouth Disease Virus , Foot-and-Mouth Disease/prevention & control , Ribavirin/therapeutic use , Viral Vaccines/therapeutic use , Animals , Antiviral Agents/administration & dosage , Cell Line , Drug Synergism , Foot-and-Mouth Disease/drug therapy , Injections, Intramuscular , Injections, Intraperitoneal , Mice , Mice, Inbred C57BL , Ribavirin/administration & dosage , Swine , Swine, Miniature , Viral Vaccines/administration & dosage
16.
Biomed Res Int ; 2017: 2481348, 2017.
Article in English | MEDLINE | ID: mdl-29226127

ABSTRACT

Foot-and-mouth disease virus (FMDV) is the etiological agent of FMD, which affects domestic and wild cloven-hoofed animals. The structural protein VP1 plays an important role in FMDV pathogenesis. However, the interacting partners of VP1 in host cells and the effects of these interactions in FMDV replication remain incompletely elucidated. Here, we identified a porcine cell protein, serine/threonine kinase 3 (STK3), which interacts with FMDV VP1 using the yeast two-hybrid system. The VP1-STK3 interaction was further confirmed by coimmunoprecipitation experiments in human embryonic kidney 293T and porcine kidney 15 (PK-15) cells. The carboxyl-terminal region (amino acids 180-214) of VP1 was essential for its interaction with STK3. The effects of overexpression and underexpressing of STK3 in PK-15 cells were assessed, and the results indicated that STK3 significantly inhibited FMDV replication. Our data expand the role of STK3 during viral infection, provide new information regarding the host cell kinases that are involved in viral replication, and identify potential targets for future antiviral strategies.


Subject(s)
Capsid Proteins/metabolism , Protein Serine-Threonine Kinases/metabolism , Viral Proteins/metabolism , Virus Replication/physiology , Animals , Antiviral Agents/pharmacology , Cell Line , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease/virology , Foot-and-Mouth Disease Virus/drug effects , HEK293 Cells , Humans , Swine , Virus Replication/drug effects
17.
Pak J Pharm Sci ; 30(6): 2165-2172, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29175786

ABSTRACT

Cytotoxic and antiviral activity of aqueous leaves extracts of three plants: Azadirachta indica, Moringa oleifera and Morus alba against Foot and Mouth disease virus (FMDV) were determined using MTT assay (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide). Eight different concentrations of each plant were evaluated. Cytotoxic and antiviral activity of each extract was evaluated as cell survival percentage and results were expressed as Means ± S.D. From the tested plant extracts, Azadirachta indica & Moringa oleifera exhibited cytotoxicity at 200 & 100 µ/ml respectively. In case of antiviral assay, Moringa oleifera showed potent antiviral activity (p<0.05) while Azadirachta indica showed significant antiviral activity in the range of 12.5-50 µ/ml & 50-100 µ/ml respectively. In contrast no anti-FMDV activity in the present study was observed with Morus alba, although all the tested concentrations were found to be safe.


Subject(s)
Agriculture , Antiviral Agents/pharmacology , Azadirachta/chemistry , Foot-and-Mouth Disease Virus/drug effects , Foot-and-Mouth Disease/drug therapy , Moringa oleifera/chemistry , Plant Extracts/pharmacology , Plant Leaves/chemistry , Veterinary Drugs/pharmacology , Animals , Antiviral Agents/isolation & purification , Antiviral Agents/toxicity , Azadirachta/toxicity , Cell Line , Cricetinae , Dose-Response Relationship, Drug , Farms , Foot-and-Mouth Disease/diagnosis , Foot-and-Mouth Disease/virology , Foot-and-Mouth Disease Virus/pathogenicity , Moringa oleifera/toxicity , Plant Extracts/isolation & purification , Plant Extracts/toxicity , Plant Leaves/toxicity , Veterinary Drugs/isolation & purification , Veterinary Drugs/toxicity
18.
Lett Appl Microbiol ; 65(4): 281-284, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28736948

ABSTRACT

An evaluation was made of the efficacy of 35% hydrogen peroxide vapour (HPV) against foot-and-mouth disease virus (FMDV) in a biosafety facility. Biological indicators (BIs) were produced using three serotypes of FMDV, all with a titre of ≥106 TCID50 per ml. Fifteen BIs of each serotype were distributed across five locations, throughout a 30-m3 airlock chamber, producing a total of 45 BIs. Thirty-five percent HPV was generated and applied using a Bioquell vaporization module located in the centre of the chamber. After a dwell period of 40 min, the HPV was removed via the enclosures air handling system and the BIs were collected. The surfaces of the BIs were recovered into Glasgow's modified Eagle's medium (GMEM), cultivated in BHK21 Cl13 cell culture and analysed for evidence of cytopathic effect (CPE). No CPE was detected in any BI sample. Positive controls showed CPE. The experimentation shows that FMDV is susceptible to HPV decontamination and presents a potential alternative to formaldehyde. SIGNIFICANCE AND IMPACT OF THE STUDY: Foot-and-mouth disease virus (FMDV) is an important pathogen in terms of biosafety due to its infectious nature and wide range of host animals, such as cattle, sheep, goats and pigs. Outbreaks of FMDV can have a severe impact on livestock production, causing morbidity, mortality, reduced yields and trade embargoes. Laboratories studying FMDV must possess BSL4 robust bio-decontamination methods to prevent inadvertent release. Formaldehyde has been the primary agent for environmental decontamination, but its designation as a human carcinogen has led to a search for alternatives. This study shows 35% hydrogen peroxide vapour has the potential to be a rapid, effective, residue-free alternative.


Subject(s)
Containment of Biohazards/methods , Decontamination/methods , Disease Outbreaks/veterinary , Disinfectants/pharmacology , Foot-and-Mouth Disease Virus/drug effects , Foot-and-Mouth Disease/drug therapy , Hydrogen Peroxide/pharmacology , Animals , Cattle , Cattle Diseases/prevention & control , Cattle Diseases/virology , Foot-and-Mouth Disease/virology , Goat Diseases/prevention & control , Goat Diseases/virology , Goats , Sheep , Sheep Diseases/prevention & control , Sheep Diseases/virology , Swine , Swine Diseases/prevention & control , Swine Diseases/virology
19.
Article in English | MEDLINE | ID: mdl-28660175

ABSTRACT

Foot-and-mouth disease virus (FMDV) is the causative agent of an acute vesicular disease affecting pigs, cattle and other domestic, and wild animals worldwide. The aim of the host interferon (IFN) response is to limit viral replication and spread. Detection of the viral genome and products by specialized cellular sensors initiates a signaling cascade that leads to a rapid antiviral response involving the secretion of type I- and type III-IFNs and other antiviral cytokines with antiproliferative and immunomodulatory functions. During co-evolution with their hosts, viruses have acquired strategies to actively counteract host antiviral responses and the balance between innate response and viral antagonism may determine the outcome of disease and pathogenesis. FMDV proteases Lpro and 3C have been found to antagonize the host IFN response by a repertoire of mechanisms. Moreover, the putative role of other viral proteins in IFN antagonism is being recently unveiled, uncovering sophisticated immune evasion strategies different to those reported to date for other members of the Picornaviridae family. Here, we review the interplay between antiviral responses induced by FMDV infection and viral countermeasures to block them. Research on strategies used by viruses to modulate immunity will provide insights into the function of host pathways involved in defense against pathogens and will also lead to development of new therapeutic strategies to fight virus infections.


Subject(s)
Antiviral Agents/pharmacology , Foot-and-Mouth Disease Virus/drug effects , Foot-and-Mouth Disease Virus/immunology , Foot-and-Mouth Disease/drug therapy , Host-Pathogen Interactions/immunology , Immunity, Innate , Animals , Cytokines/pharmacology , Foot-and-Mouth Disease/immunology , Foot-and-Mouth Disease/metabolism , Foot-and-Mouth Disease/virology , Foot-and-Mouth Disease Virus/pathogenicity , Genome, Viral , Immune Evasion , Interferons/pharmacology , Peptide Hydrolases/immunology , RNA, Viral/immunology , Signal Transduction , Viral Proteins/immunology , Viral Proteins/metabolism , Virus Replication/drug effects
20.
J Med Virol ; 89(11): 2041-2046, 2017 11.
Article in English | MEDLINE | ID: mdl-28390158

ABSTRACT

Foot-and-mouth disease virus (FMDV) causes an economically important and highly contagious disease of cloven-hoofed animals such as cattle, swine, and sheep. FMD vaccine is the traditional way to protect against the disease, which can greatly reduce its occurrence. However, the use of FMD vaccines to protect early infection is limited. Therefore, the alternative strategy of applying antiviral agents is required to control the spread of FMDV in outbreak situations. As previously reported, LiCl has obviously inhibition effects on a variety of viruses such as transmissible gastroenteritis virus (TGEV), infectious bronchitis coronavirus (IBV), and pseudorabies herpesvirus and EV-A71 virus. In this study, our findings were the first to demonstrate that LiCl inhibition of the FMDV replication. In this study, BHK-21 cell was dose-dependent with LiCl at various stages of FMDV. Virus titration assay was calculated by the 50% tissue culture infected dose (TCID50 ) with the Reed and Muench method. The cytotoxicity assay of LiCl was performed by the CCK8 kit. The expression level of viral mRNA was measured by RT-qPCR. The results revealed LiCl can inhibit FMDV replication, but it cannot affect FMDV attachment stage and entry stage in the course of FMDV life cycle. Further studies confirmed that the LiCl affect the replication stage of FMDV, especially the early stages of FMDV replication. So LiCl has potential as an effective anti-FMDV drug. Therefore, LiCl may be an effective drug for the control of FMDV. Based on that, the mechanism of the antiviral effect of LiCl on FMDV infection is need to in-depth research in vivo.


Subject(s)
Antiviral Agents/pharmacology , Foot-and-Mouth Disease Virus/drug effects , Lithium Chloride/pharmacology , Virus Replication/drug effects , Animals , Cattle , Cell Line , DNA Replication/drug effects , Foot-and-Mouth Disease/drug therapy , Foot-and-Mouth Disease/virology , Foot-and-Mouth Disease Virus/genetics , Foot-and-Mouth Disease Virus/physiology , Polymerase Chain Reaction , RNA, Viral/genetics , Sheep , Swine , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...